A random forest model to predict the efficacy of anti-PD-1/PD-L1 monoclonal antibody in lung adenocarcinoma

被引：0

作者：

Xie, Tongji

Li, Yan

Yang, Lin

Wu, Lige

Yuan, Hanqi

Ying, Jianming

Li Junling

Xing, Puyuan

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Dept Pathol, State Key Lab Mol Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China

[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Med Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc, Beijing, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e20558

引用

页数：1

共 50 条

[31] Thiazolidinedione enhances the efficacy of anti-PD-1 monoclonal antibody in murine melanoma
Zhang, Xinyi
Gao, Yuan
Tang, Keyun
Li, Zongyu
Halberstam, Alexandra A.
Zhou, Liqun
Perry, Rachel J.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2024, 326 (03): : E341 - E350
[32] Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
Zhang, Yiru
Yao, Qigu
Pan, Yong
Fang, Xinru
Xu, Haoying
Zhao, Tingxiao
Zhu, Guangqi
Jiang, Tianan
Li, Shibo
Cao, Hongcui
CANCERS, 2023, 15 (03)
[33] Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475
Kefford, Richard
Ribas, Antoni
Hamid, Omid
Robert, Caroline
Daud, Adil
Wolchok, Jedd D.
Joshua, Anthony M.
Hodi, F. Stephen
Gangedher, Tara C.
Hersey, Peter
Weber, Jeffrey S.
Dronca, Roxana Stefanie
Patnaik, Amite
Zarour, Hassans M.
Dolled-Filhart, Marisa
Lunceford, Jared
Emancipator, Kenneth
Ebbinghaus, Scot
Rang, Soonmo Peter
Hwu, Wen-Jen
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[34] Assessment of Adverse Events and Their Ability to Discriminate Response to Anti-PD-1/PD-L1 Antibody Immunotherapy
McLeod, Howard L.
Mariam, Arshiya
Schveder, Kimberly A.
Rotroff, Daniel M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (01) : 103 - +
[35] A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
Albu, Diana I.
Wolf, Benjamin J.
Qin, Yan
Wang, Xianzhe
Ulumben, Amy Daniel
Su, Mei
Li, Vivian
Ding, Eirene
Gonzalo, Jose Angel
Kong, Jason
Jadhav, Ruturaj
Kuklin, Nelly
Visintin, Alberto
Gong, Bing
Schuetz, Thomas J.
ONCOIMMUNOLOGY, 2024, 13 (01):
[36] MHC Class I and PD-L1 Expression May Predict Treatment Response to Anti-PD-1/PD-L1 Therapy in Breast Cancer Patients
Maniaci, Joseph
Mills, Anne
Dillon, Patrick
Gaughan, Elizabeth
Jenkins, Taylor
LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 160 - 161
[37] MHC Class I and PD-L1 Expression May Predict Treatment Response to Anti-PD-1/PD-L1 Therapy in Breast Cancer Patients
Maniaci, Joseph
Mills, Anne
Dillon, Patrick
Gaughan, Elizabeth
Jenkins, Taylor
MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 160 - 161
[38] Intrinsic suppression of PD-L1 by SOX10 affects anti-PD-1 efficacy in melanoma
Takahashi, Atsushi
Yokoyama, Satoru
Zhou, Yue
Hayakawa, Yoshihiro
Sakurai, Hiroaki
CANCER SCIENCE, 2022, 113 : 513 - 513
[39] Predictive immunological markers of anti-PD-1/PD-L1 therapy efficacy in non-small cell lung cancer
Musaelyan, A. A.
Lapin, S. V.
Urtenova, M. A.
Chistyakov, I. V.
Nazarov, V. D.
Akopov, A. L.
Orlov, S. V.
ANNALS OF ONCOLOGY, 2021, 32 : S1382 - S1382
[40] Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
Zeng, Tian
Qin, Qin
Bian, Zhiheng
Li, Jianjun
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2019, 47 (01) : 4194 - 4201

← 1 2 3 4 5 →